PROTOKINETIX BLOG

Find out how AAGP® is changing lives through cell survival

As we move forward with clinical research for our anti-aging glycopeptide, AAGP®, we continue to uncover new areas of opportunity for the molecule. See how AAGP® is helping to provide more hope for patients and investors in the areas of ophthalmology, transplants, dermatology and biomanufacturing.

Nov 24, 2020

bybhenderson

Research Paper Showing ProtoKinetix AAGP® Enhanced Stem Cell Derived Retina Precursor Cells Restoration of Vision

Marietta, Ohio, November 24, 2020 ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB: PKTX), a clinical-stage biomedical company, today announced the submission of a research paper describing and interpreting the results analysing the benefit of PKX-001 on human induced pluripotent stem cell (iPSC) derived retinal precursor cells transplanted to an experimental model of blindness due to...Read more

Oct 30, 2020

byprotokinetixp

AAGP® | biotechnology | biotechnology investments | dry-eye | market opportunity

Biotech Investing: How to Pick a Winner

The promise of biotechnology stocks to the average investor is the potential for blazing growth and incredible returns. But not every company pays dividends on that promise. Too many times, investors have been burned by biotech stocks that burn fast and bright before completely flaming out. What these investors are looking for is not just...Read more

Subscribe for updates

Get alerts about company news and key findings directly in your inbox.

Request More Information

Talk to a member of the ProtoKinetix team to learn more about our research and results.